Search
Now showing items 1-10 of 69
Combining ibrutinib and checkpoint blockade improves CD8(+) T-cell function and control of chronic lymphocytic leukemia in E mu-TCL1 mice
Hanna, Bola S. et al. (2021)
Wissenschaftlicher Artikel
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Byrd, John C. et al. (2021)
Wissenschaftlicher Artikel
Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
Cramer, Paula et al. (2021)
Wissenschaftlicher Artikel
Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study
Davids, Matthew S. et al. (2020)
Wissenschaftlicher Artikel
Activation of Notch and Myc Signaling via B-cell-Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia
Biran, Anat et al. (2021)
Wissenschaftlicher Artikel
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
Hoechstetter, Manuela A. et al. (2020)
Wissenschaftlicher Artikel
Interleukin-10 receptor signaling promotes the maintenance of a PD-1(i)(nt) TCF-1(+) CD8(+) T cell population that sustains anti-tumor immunity
Hanna, Bola S. et al. (2021)
Wissenschaftlicher Artikel
Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL
Wierzbinska, Justyna A. et al. (2020)
Wissenschaftlicher Artikel
BIRC3 mutations in chronic lymphocytic leukemia - uncommon and unfavorable
Tausch, Eugen; Stilgenbauer, Stephan (2020)
Wissenschaftlicher Artikel
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
Al-Sawaf, Othman et al. (2021)
Wissenschaftlicher Artikel